ClinicalTrials.gg
RecruitingNCT06891833Updated Oct 27, 2026

A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

A Phase 2/3 interventional study of BL-M07D1 and Pertuzumab in HER2-positive Breast Cancer, sponsored by Sichuan Baili Pharmaceutical Co., Ltd.. Recruiting at 30 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Sichuan Baili Pharmaceutical Co., Ltd. (part of Sichuan Biokin Pharmaceutical Co., Ltd.) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Oct 27, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
985
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Breast Neoplasms by Sichuan Biokin Pharmaceutical Co., Ltd. — 15 open to participants now, 20 under way, 7 of them phase 3. Breast Neoplasms · Sichuan Biokin Pharmaceutical Co., Ltd..

Planned enrollment
2nd of 22
985 · median 83
Started
2025
with 4 others
Phase 2/3
Only one
of the 22
Primary completion
2028-12
later than 13 of 19 live
Registered
16th of 22
by date

Among the 22 studies in Breast Neoplasms by Sichuan Biokin Pharmaceutical Co., Ltd., this one is the 2nd largest by planned enrollment, is one of 5 that started in 2025, is the only one in phase 2/3, reaches primary completion later than 13 of the 19 other live ones, and was the 16th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

15 of the 22 studies in Breast Neoplasms by Sichuan Biokin Pharmaceutical Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Breast Neoplasms by Sichuan Biokin Pharmaceutical Co., Ltd., or all of them as a file.
02

Study summary

This trial is a registered phase III, randomized, open and multicenter study to evaluate the efficacy and safety of BL-M07D1 with or without Pertuzumab in the neoadjuvant treatment of HER2-positive breast cancer. The study is divided into a single-arm study phase (Phase II) and a randomized controlled study phase (Phase III).

03

Conditions studied

  • HER2-positive Breast Cancer

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form and comply with protocol requirements;
  2. Female aged ≥18 and ≤75 years at the time of signing the informed consent form;
  3. Expected survival time ≥6 months;
  4. Patients with -positive invasive breast cancer confirmed by histological examination;
  5. Clinical stage II-III confirmed based on the 8th edition of the American Joint Committee on Cancer (AJCC) staging system before therapy;
  6. Treatment-naive trial participants who have not received any anti-tumor therapy for breast cancer;
  7. Trial participants agree to undergo mastectomy or breast-conserving surgery after completion of neoadjuvant therapy;
  8. (ECOG) performance status score of 0 or 1;
  9. Organ function levels must meet the requirements;
  10. For premenopausal women of , a pregnancy test must be performed within 7 days before starting treatment; serum pregnancy must be negative, and the patient must be non-lactating; all enrolled patients should adopt adequate highly effective measures throughout the entire treatment cycle and for 7 months after treatment completion.

Exclusion criteria

Exclusion Criteria:

  1. History of breast cancer and tumor treatment;
  2. Diagnosis of other primary within 5 years before the first dose;
  3. History of severe cardiovascular or cerebrovascular disease within 6 months before screening;
  4. Prolonged , complete left bundle branch block, third-degree atrioventricular block, or frequent and uncontrolled arrhythmias;
  5. Hypertension inadequately controlled with two antihypertensive medications;
  6. Concurrent pulmonary disease resulting in severe impairment of pulmonary function;
  7. History of interstitial lung disease/interstitial pneumonia requiring therapy, etc.;
  8. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;
  9. Positive antibody, active virus infection, or virus infection;
  10. Patients with poorly controlled blood glucose;
  11. Severe infection within 4 weeks before the first use of the study drug; active pulmonary inflammation at screening;
  12. Receiving systemic corticosteroid therapy at >10 mg/day prednisone or equivalent anti-inflammatory activity, or any form of therapy, within 2 weeks before the first dose;
  13. Known to the study treatment or any study drug or other monoclonal antibodies;
  14. Patients unsuitable for receiving the drug;
  15. History of or allogeneic stem cell transplantation or organ transplantation;
  16. Severe neurological or psychiatric disorders;
  17. Subjects with bleeding or a significant bleeding tendency within 4 weeks before signing ;
  18. Intestinal obstruction, Crohn's disease, ulcerative colitis, or chronic diarrhea, etc.;
  19. Subjects planning to receive, or having received, within 28 days before the first dose;
  20. Presence of other severe physical or laboratory abnormalities or poor compliance, etc., which may increase the risk of participating in the study or interfere with study results, or patients deemed unsuitable for participation in this study by the investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
985 participants (estimated)

Study arms

  • Experimental
    Study treatment

    Participants receive BL-M07D1 with or without Pertuzumab for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

    Drug: BL-M07D1 · Drug: Pertuzumab

  • Active comparator
    docetaxel + carboplatin + trastuzumab + pertuzumab

    Participants receive docetaxel + carboplatin + trastuzumab + pertuzumaby in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

    Drug: Pertuzumab · Drug: docetaxel · Drug: carboplatin · Drug: trastuzumab

Interventions

  • Administration by intravenous infusion for a cycle of 3 weeks.

  • Administration by intravenous infusion for a cycle of 3 weeks.

  • Administration by intravenous infusion for a cycle of 3 weeks.

  • Administration by intravenous infusion for a cycle of 3 weeks.

  • Administration by intravenous infusion for a cycle of 3 weeks.

06

What researchers measure

Primary outcomes

  1. Pathological complete response (pCR) rate

    Pathological complete response (pCR) rate will be investigated.

    Time frame: Up to approximately 48 months

Secondary outcomes

  1. Event-free survival (EFS)

    Event-free survival (EFS) is defined as the time between the day the subject is randomized and the first occurrence of any event.

    Time frame: Up to approximately 48 months

  2. Invasive disease-free survival (IDFS)

    Invasive disease-free survival (IDFS) is defined as the time interval from the date of radical surgery to the presence of ipsilateral or contralateral recurrence of invasive breast cancer, locoregional recurrence, distant recurrence, or death from any cause, whichever occurs first.

    Time frame: Up to approximately 48 months

  3. Overall Survival (OS)

    Overall survival (OS) is defined as the time between the day the subject is randomized and the subject's death.

    Time frame: Up to approximately 48 months

  4. Treatment Emergent Adverse Event (TEAE)

    TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-M07D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-M07D1.

    Time frame: Up to approximately 48 months

  5. Pathologic complete response (pCR) rate as assessed by the pathologists

    Pathologic complete response (pCR) rate as assessed by the pathologists at the participating study centers will be investigated.

    Time frame: Up to approximately 48 months

  6. Objective Response Rate (ORR)

    Objective response rate (ORR) is defined as the number of CR and PR in the treatment and control groups divided by the number of that group in the full analysis set (FAS).

    Time frame: Up to approximately 24 months

07

Study locations

1 of 30 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2028, 42 months after the start.

Of 56 phase 2/3 interventional studies under Breast Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's planned 42 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Mar 24, 2025
StartActual
Jun 5, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
9 inclusion criteria edited, 2 removed; 15 exclusion criteria edited, 5 added, 5 removed
What changed in the criteria
Inclusion criteria
  • EditedVoluntarily signedsign the informed consent form and followed the programcomply with protocol requirements;
  • EditedFemalesFemale aged ≥18 and ≤75 years of age at the time of signing the informed consent form;
  • EditedPatients with HER2-positive invasive breast cancer confirmed by histologichistological examination;
  • RemovedClear hormone receptor (HR) status;
  • EditedClear clinicalClinical stage II-III confirmed based on the 8th edition of the American Joint Committee on Cancer (AJCC) staging 8th edition prior tosystem before neoadjuvant therapy;
  • ChangedBefore Primary subjects without antitumor therapy for breast cancer;Now Treatment-naive trial participants who have not received any anti-tumor therapy for breast cancer;
  • EditedSubjects consentingTrial participants agree to undergo mastectomy or breast-conserving surgery at the endafter completion of neoadjuvant therapy;
  • RemovedRadical surgery to the last dose of neoadjuvant therapy at least 2 weeks apart and up to 6 weeks apart;
  • EditedPhysicalEastern Cooperative Oncology Group (ECOG) performance status score ECOGof 0 or 1;
  • ChangedBefore Organ function levels must be met provided that blood transfusions are not permitted within 14 days prior to the first administration of study drug, colony-stimulating factors are not permitted, and so on;Now Organ function levels must meet the requirements;
  • EditedFor premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days prior to initiation ofbefore starting treatment,; serum pregnancy must be negative, and the patient must be non-lactating; all enrolled patients should be usingadopt adequate and highly effective contraceptioncontraceptive measures throughout the entire treatment cycle and for 7 months after treatment completion of treatment.
Exclusion criteria
  • EditedDiagnosisHistory of stage IV metastatic breast cancer and tumor treatment;
  • RemovedBilateral breast cancer;
  • RemovedPrior history of any breast cancer (unilateral or contralateral) other than lobular carcinoma in situ (LCIS);
  • EditedDiagnosis of anotherother primary malignancymalignancies within 5 years prior tobefore the first dose;
  • EditedHistory of severe cardiovascular or cerebrovascular disease within 6 months prior tobefore screening;
  • EditedProlonged QTQTc interval, complete left bundle branch block, third-degree III atrioventricular block, andor frequent and uncontrollableuncontrolled arrhythmias;
  • RemovedPoorly controlled hypertension (systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg);
  • RemovedComplicated lung disease resulting in severely impaired lung function;
  • RemovedHistory of ILD / interstitial pneumonitis requiring steroid hormone therapy, current ILD / interstitial pneumonitis, or suspected of having such a disease, etc;
  • AddedHypertension inadequately controlled with two antihypertensive medications;
  • AddedConcurrent pulmonary disease resulting in severe impairment of pulmonary function;
  • AddedHistory of interstitial lung disease/interstitial pneumonia requiring steroid therapy, etc.;
  • AddedUnstable thrombotic events requiring therapeutic intervention within 6 months before screening;
  • EditedHumanPositive human immunodeficiency virus antibody positivity, active hepatitis B virus infection, cirrhosis, or hepatitis C virus infection;
  • AddedPatients with poorly controlled blood glucose;
  • EditedSevere infection within 4 weeks prior tobefore the first doseuse of the study drug; active pulmonary inflammation present at screening;
  • EditedOngoing treatment withReceiving systemic corticosteroid therapy at >10 mg/dday prednisone systemic corticosteroid therapy or equivalent anti-inflammatory active drugactivity, or any form of immunosuppressive therapy, within 2 weeks prior tobefore the first dose;
  • EditedKnown hypersensitivity to the study therapeutic drugtreatment or any study drug excipients or other monoclonal antibodies;
  • ChangedBefore Patients who are not suitable to receive the investigational drug (paclitaxel, patulizumab, trastuzumab);Now Patients unsuitable for receiving the investigational drug;
  • EditedHave a historyHistory of autologous or allogeneic stem cell transplantation or organ transplantation;
  • EditedSuffering from severeSevere neurological or psychiatric disorders;
  • EditedSubjects with clinically significant bleeding or a significant bleeding tendency within 4 weeks prior tobefore signing the informationinformed consent;
  • EditedIntestinal obstruction, Crohn's disease, ulcerative colitis, or chronic diarrhea, etc.;
  • EditedSubjects who are scheduledplanning to receive a, or having received, live vaccine or who have received a live vaccinevaccines within 28 days prior tobefore the first dose;
  • EditedPresence of other serioussevere physical, or laboratory test abnormalities or poor compliance that, etc., which may increase the risk of participationparticipating in the study or interfere with the study results, as well asor patients who, in the opinion of the investigator, are not suitabledeemed unsuitable for participation in this study by the investigator.
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Eligibility 9 inclusion criteria edited, 2 removed; 15 exclusion criteria edited, 5 added, 5 removed
    What changed in the criteria
    Inclusion criteria
    • EditedVoluntarily signedsign the informed consent form and followed the programcomply with protocol requirements;
    • EditedFemalesFemale aged ≥18 and ≤75 years of age at the time of signing the informed consent form;
    • EditedPatients with HER2-positive invasive breast cancer confirmed by histologichistological examination;
    • RemovedClear hormone receptor (HR) status;
    • EditedClear clinicalClinical stage II-III confirmed based on the 8th edition of the American Joint Committee on Cancer (AJCC) staging 8th edition prior tosystem before neoadjuvant therapy;
    • ChangedBefore Primary subjects without antitumor therapy for breast cancer;Now Treatment-naive trial participants who have not received any anti-tumor therapy for breast cancer;
    • EditedSubjects consentingTrial participants agree to undergo mastectomy or breast-conserving surgery at the endafter completion of neoadjuvant therapy;
    • RemovedRadical surgery to the last dose of neoadjuvant therapy at least 2 weeks apart and up to 6 weeks apart;
    • EditedPhysicalEastern Cooperative Oncology Group (ECOG) performance status score ECOGof 0 or 1;
    • ChangedBefore Organ function levels must be met provided that blood transfusions are not permitted within 14 days prior to the first administration of study drug, colony-stimulating factors are not permitted, and so on;Now Organ function levels must meet the requirements;
    • EditedFor premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days prior to initiation ofbefore starting treatment,; serum pregnancy must be negative, and the patient must be non-lactating; all enrolled patients should be usingadopt adequate and highly effective contraceptioncontraceptive measures throughout the entire treatment cycle and for 7 months after treatment completion of treatment.
    Exclusion criteria
    • EditedDiagnosisHistory of stage IV metastatic breast cancer and tumor treatment;
    • RemovedBilateral breast cancer;
    • RemovedPrior history of any breast cancer (unilateral or contralateral) other than lobular carcinoma in situ (LCIS);
    • EditedDiagnosis of anotherother primary malignancymalignancies within 5 years prior tobefore the first dose;
    • EditedHistory of severe cardiovascular or cerebrovascular disease within 6 months prior tobefore screening;
    • EditedProlonged QTQTc interval, complete left bundle branch block, third-degree III atrioventricular block, andor frequent and uncontrollableuncontrolled arrhythmias;
    • RemovedPoorly controlled hypertension (systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg);
    • RemovedComplicated lung disease resulting in severely impaired lung function;
    • RemovedHistory of ILD / interstitial pneumonitis requiring steroid hormone therapy, current ILD / interstitial pneumonitis, or suspected of having such a disease, etc;
    • AddedHypertension inadequately controlled with two antihypertensive medications;
    • AddedConcurrent pulmonary disease resulting in severe impairment of pulmonary function;
    • AddedHistory of interstitial lung disease/interstitial pneumonia requiring steroid therapy, etc.;
    • AddedUnstable thrombotic events requiring therapeutic intervention within 6 months before screening;
    • EditedHumanPositive human immunodeficiency virus antibody positivity, active hepatitis B virus infection, cirrhosis, or hepatitis C virus infection;
    • AddedPatients with poorly controlled blood glucose;
    • EditedSevere infection within 4 weeks prior tobefore the first doseuse of the study drug; active pulmonary inflammation present at screening;
    • EditedOngoing treatment withReceiving systemic corticosteroid therapy at >10 mg/dday prednisone systemic corticosteroid therapy or equivalent anti-inflammatory active drugactivity, or any form of immunosuppressive therapy, within 2 weeks prior tobefore the first dose;
    • EditedKnown hypersensitivity to the study therapeutic drugtreatment or any study drug excipients or other monoclonal antibodies;
    • ChangedBefore Patients who are not suitable to receive the investigational drug (paclitaxel, patulizumab, trastuzumab);Now Patients unsuitable for receiving the investigational drug;
    • EditedHave a historyHistory of autologous or allogeneic stem cell transplantation or organ transplantation;
    • EditedSuffering from severeSevere neurological or psychiatric disorders;
    • EditedSubjects with clinically significant bleeding or a significant bleeding tendency within 4 weeks prior tobefore signing the informationinformed consent;
    • EditedIntestinal obstruction, Crohn's disease, ulcerative colitis, or chronic diarrhea, etc.;
    • EditedSubjects who are scheduledplanning to receive a, or having received, live vaccine or who have received a live vaccinevaccines within 28 days prior tobefore the first dose;
    • EditedPresence of other serioussevere physical, or laboratory test abnormalities or poor compliance that, etc., which may increase the risk of participationparticipating in the study or interfere with the study results, as well asor patients who, in the opinion of the investigator, are not suitabledeemed unsuitable for participation in this study by the investigator.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06891833
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 24, 2025
Start date
Jun 5, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

Sa Xiao, PHD
Contact
xiaosa@baili-pharm.com
15013238943

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-HER2 Antibody-drug Conjugate BL-M07D1

Start the discussion